Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Q32 Bio ( (QTTB) ) has shared an announcement.
Q32 Bio announced updates to its corporate presentation, highlighting the progress in clinical trials for its lead products. The company is advancing its bempikibart program, demonstrating potential in treating alopecia areata with durable effects and favorable safety, and plans to initiate a Phase 2a Part B trial. Additionally, ADX-097 is being tested in a Phase 2 renal basket trial, with multiple data readouts expected in 2025, positioning Q32 for significant growth opportunities.
More about Q32 Bio
Q32 Bio is a company focused on developing immune therapeutics, particularly targeting Th1 and Th2 mediated diseases through its proprietary platforms. Its primary products include bempikibart and ADX-097, which aim to address conditions such as alopecia areata and renal diseases.
YTD Price Performance: -3.19%
Average Trading Volume: 351,207
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $40.68M
For detailed information about QTTB stock, go to TipRanks’ Stock Analysis page.
